GERD With Erosive Esophagitis Clinical Trial
Official title:
A Randomised, Double-blind, Multicentre Dose-finding Phase IIb Study for up to 8 Weeks' Treatment With AZD0865 25, 50, 75 mg and Esomeprazole 40 mg, Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult Subjects With GERD With Erosive Esophagitis According to the LA Classification in Adult Subjects.
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and
75 mg).
The secondary objectives are to compare the efficacy between the three doses of AZD0865 and
esomeprazole 40 mg and to evaluate the safety and tolerability of AZD0865.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment